Sebastian Albers

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Low Density Lipoprotein

Top Venues

European journal of cancer care

Journal of the National Cancer Institute

BMJ evidence-based medicine

American journal of cardiovascular drugs : drugs, devices, and other interventions

This page only lists publications with an associated author ORCID identifier.

Publications

Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli
Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications. BMJ evidence-based medicine (2024)
Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs. Targeted oncology (2024)
Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Tobias Boch, Julia Caroline Michaeli
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. The European journal of health economics : HEPAC : health economics in prevention and care (2023)
Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, Tobias Boch, Thomas Michaeli
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli
Clinical benefit, development, innovativeness, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations. Journal of the National Cancer Institute (2023)
Julia Caroline Michaeli, Daniel Tobias Michaeli, Tobias Boch, Sebastian Albers, Thomas Michaeli
Socio-economic burden of disease: Survivorship costs for renal cell carcinoma. European journal of cancer care 31 (3) (2022)